



Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome

June 23, 2021

Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3K δ) syndrome (APDS).